It is also important to acknowledge that SGLT-2 inhibitors and GLP-1 analogs, which were not included in our analysis due to the cohort being established before the completion of relevant RCTs, could potentially influence the incidence of AKI and its association with MACE. The gene discussed is SLC5A2; the disease is acute kidney injury.